Drugs & aging · 2026
Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
da Silva Anderson Matheus Pereira, Leite Marianna, Menegucci Giovana, Negreli Maria Fernanda Liphaus Almeida, Valverde Maria Eduarda Scheffer, Menezes Isabelle Rodrigues, Gonçalves Ocilio Ribeiro, da Silva Lapa Jorge Dornellys, Noleto Gustavo, Santos Diogo Haddad, Duarte Filipe Silveira, Perry George, de Souza Franco Eryvelton, de Sousa Maia Maria Bernadete
Аннотация
BACKGROUND AND OBJECTIVE: Gabapentinoids, particularly gabapentin and pregabalin, are widely prescribed for neuropathic pain and other chronic conditions, including in populations at risk for cognitive decline. Their long-term cognitive safety and potential association with Alzheimer's disease and related dementias (ADRD) remain uncertain. We examined whether gabapentinoid use is associated with ADRD risk and assessed between-study heterogeneity and potential study-level modifiers.
METHODS: PubMed, Embase, and the Cochrane Library were searched from inception through November 2025. We included observational studies comparing gabapentinoid users with non-users or non-gabapentinoid comparators and reporting incident ADRD. Risk of bias was assessed using ROBINS-E. A random-effects meta-analysis was performed using odds ratios. Subgroup and meta-regression analyses explored study-level modifiers. Certainty of evidence was assessed using GRADE (Grading of Recommendations Assessment, Development and Evaluation). The protocol was registered in PROSPERO (CRD420251240055).
RESULTS: Five observational studies (325,245 participants) were included. Gabapentinoid use was associated with modestly higher estimated odds of ADRD (odds ratio, 1.28; 95% confidence interval 1.10-1.50; P = 0.002), with high heterogeneity (I2 = 90.3%). This association was attenuated when restricted to studies with a low risk of bias (odds ratio, 1.23; 95% confidence interval 0.83-1.84). Studies enrolling younger populations yielded larger estimates than those with older cohorts, though the subgroup difference was not statistically significant. Meta-regression identified mean age as a study-level moderator, accounting for 60.2% of between-study variance. Certainty of evidence was low overall.
CONCLUSIONS: Gabapentinoid use was associated with modestly higher estimated odds of ADRD in pooled observational data. High heterogeneity, residual confounding, and confounding by indication preclude causal inference. These findings support cautious prescribing, particularly for off-label and long-term use, and underscore the need for prospective studies.
CLINICAL TRIAL REGISTRATION: PROSPERO protocol number: CRD420251240055.
METHODS: PubMed, Embase, and the Cochrane Library were searched from inception through November 2025. We included observational studies comparing gabapentinoid users with non-users or non-gabapentinoid comparators and reporting incident ADRD. Risk of bias was assessed using ROBINS-E. A random-effects meta-analysis was performed using odds ratios. Subgroup and meta-regression analyses explored study-level modifiers. Certainty of evidence was assessed using GRADE (Grading of Recommendations Assessment, Development and Evaluation). The protocol was registered in PROSPERO (CRD420251240055).
RESULTS: Five observational studies (325,245 participants) were included. Gabapentinoid use was associated with modestly higher estimated odds of ADRD (odds ratio, 1.28; 95% confidence interval 1.10-1.50; P = 0.002), with high heterogeneity (I2 = 90.3%). This association was attenuated when restricted to studies with a low risk of bias (odds ratio, 1.23; 95% confidence interval 0.83-1.84). Studies enrolling younger populations yielded larger estimates than those with older cohorts, though the subgroup difference was not statistically significant. Meta-regression identified mean age as a study-level moderator, accounting for 60.2% of between-study variance. Certainty of evidence was low overall.
CONCLUSIONS: Gabapentinoid use was associated with modestly higher estimated odds of ADRD in pooled observational data. High heterogeneity, residual confounding, and confounding by indication preclude causal inference. These findings support cautious prescribing, particularly for off-label and long-term use, and underscore the need for prospective studies.
CLINICAL TRIAL REGISTRATION: PROSPERO protocol number: CRD420251240055.